Lactoferrin knockout mice demonstrates greater susceptibility to aggregatibacter actinomycetemcomitans-induced periodontal disease

Journal of Periodontology

Volumn 84, Issue 11, 2013, Pages 1690-1701

  Velusamy, S K ^a   Ganeshnarayan, K ^a   Markowitz, K ^a   Schreiner, H ^a   Furgang, D ^a   Fine, D H ^a   Velliyagounder, K ^a  

^a RUTGERS SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Cytokines; Lactoferrin; Periodontal disease.

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6, MOUSE; INTERLEUKIN DERIVATIVE; INTERLEUKIN-6, MOUSE; LACTOFERRIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TNFRSF11B PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA; TXLNA PROTEIN, MOUSE;

AGGREGATIBACTER ACTINOMYCETEMCOMITANS; AGGRESSIVE PERIODONTITIS; ALVEOLAR BONE LOSS; ANIMAL; ARTICLE; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DISEASE PREDISPOSITION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MICROBIOLOGY; MOUSE; PASTEURELLACEAE INFECTION; PATHOLOGY; PERIODONTIUM; SALIVA; TOOTH CERVIX;

AGGREGATIBACTER ACTINOMYCETEMCOMITANS; AGGRESSIVE PERIODONTITIS; ALVEOLAR BONE LOSS; ANIMALS; CHEMOKINES; CYTOKINES; DISEASE SUSCEPTIBILITY; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKINS; LACTOFERRIN; MICE; MICE, KNOCKOUT; OSTEOPROTEGERIN; PASTEURELLACEAE INFECTIONS; PERIODONTIUM; RANK LIGAND; RECEPTORS, CHEMOKINE; SALIVA; TOOTH CERVIX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84888346765     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2013.120587     Document Type: Article

References (48)

1. Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL JrJr. Microbial complexes in subgingival plaque. J Clin Periodontol 1998;25:134-144.
2. Aas JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE. Defining the normal bacterial flora of the oral cavity. J Clin Microbiol 2005;43:5721-5732.
3. Henderson B, Wilson M, Sharp L, Ward JM. Actinobacillus actinomycetemcomitans. J Med Microbiol 2002;51:1013-1020.
4. Shenker BJ, McKay T, Datar S, Miller M, Chowhan R, Demuth D. Actinobacillus actinomycetemcomitans immunosuppressive protein is a member of the family of cytolethal distending toxins capable of causing a G2 arrest in human T cells. J Immunol 1999;162:4773-4780.
5. Liu YC, Lerner UH, Teng YT. Cytokine responses against periodontal infection: Protective and destructive roles. Periodontol 2000 2010;52:163-206.
6. Garlet GP, Avila-Campos MJ, Milanezi CM, Ferreira BR, Silva JS. Actinobacillus actinomycetemcomitans-induced periodontal disease in mice: Patterns of cytokine, chemokine, and chemokine receptor expression and leukocyte migration. Microbes Infect 2005;7:738-747.
7. Graves DT, Fine D, Teng YT, Van Dyke TE, Hajishengallis G. The use of rodent models to investigate hostbacteria interactions related to periodontal diseases. J Clin Periodontol 2008;35:89-105.
8. Ward PP, Conneely OM. Lactoferrin: Role in iron homeostasis and host defense against microbial infection. Biometals 2004;17:203-208.
9. Weinberg ED. Human lactoferrin: A novel therapeutic with broad spectrum potential. J Pharm Pharmacol 2001;53:1303-1310.
10. Fine DH, Furgang D. Lactoferrin iron levels affect attachment of Actinobacillus actinomycetemcomitans to buccal epithelial cells. J Periodontol 2002;73:616-623.
11. Fine DH, Furgang D, Beydouin F. Lactoferrin iron levels are reduced in saliva of patients with localized aggressive periodontitis. J Periodontol 2002;73:624-630.
12. Elass-Rochard E, Legrand D, Salmon V, et al. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide- binding protein. Infect Immun 1998;66:486-491.
13. Haversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA, Mattsby-Baltzer I. Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell Immunol 2002;220:83-95.
14. Machnicki M, Zimecki M, Zagulski T. Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo. Int J Exp Pathol 1993;74:433-439.
15. Cornish J, Palmano K, Callon KE, et al. Lactoferrin and bone; structure-Activity relationships. Biochem Cell Biol 2006;84:297-302.
16. Naot D, Chhana A, Matthews BG, et al. Molecular mechanisms involved in the mitogenic effect of lactoferrin in osteoblasts. Bone 2011;49:217-224.
17. Naot D, Grey A, Reid IR, Cornish J. Lactoferrin -A novel bone growth factor. Clin Med Res 2005;3:93-101.
18. Kalfas S, Andersson M, Edwardsson S, Forsgren A, Naidu AS. Human lactoferrin binding to Porphyromonas gingivalis, Prevotella intermedia and Prevotella melaninogenica. Oral Microbiol Immunol 1991; 6:350-355.
19. Velliyagounder K, Kaplan JB, Furgang D, et al. One of two human lactoferrin variants exhibits increased antibacterial and transcriptional activation activities and is associated with localized juvenile periodontitis. Infect Immun 2003;71:6141-6147.
20. Zagulski T, Lipi-nski P, Zagulska A, Broniek S, Jarzabek Z. Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. Br J Exp Pathol 1989;70:697-704.
21. Ishikado A, Uesaki S, Suido H, et al. Human trial of liposomal lactoferrin supplementation for periodontal disease. Biol Pharm Bull 2010;33:1758-1762.
22. Shimizu E, Kobayashi T, Wakabayashi H, Yamauchi K, Iwatsuki K, Yoshie H. Effects of orally administered lactoferrin and lactoperoxidase-containing tablets on clinical and bacteriological profiles in chronic periodontitis patients. Int J Dent 2011;2011:405139.
23. Wakabayashi H, Kondo I, Kobayashi T, et al. Periodontitis, periodontopathic bacteria and lactoferrin. Biometals 2010;23:419-424.
24. Guillén C, McInnes IB, Vaughan DM, et al. Enhanced Th1 response to Staphylococcus aureus infection in human lactoferrin-transgenic mice. J Immunol 2002; 168:3950-3957.
25. Schreiner HC, Sinatra K, Kaplan JB, et al. Tightadherence genes of Actinobacillus actinomycetemcomitans are required for virulence in a rat model. Proc Natl Acad Sci U S A 2003;100:7295-7300.
26. Dixon DR, Reife RA, Cebra JJ, Darveau RP. Commensal bacteria influence innate status within gingival tissues: A pilot study. J Periodontol 2004;75: 1486-1492.
27. Yu LC,Chen YH. The developmental profile of lactoferrin in mouse epididymis. Biochem J 1993;296:107-111.
28. Schreiner H, Markowitz K, Miryalkar M, Moore D, Diehl S, Fine DH. Aggregatibacter actinomycetemcomitansinduced bone loss and antibody response in three rat strains. J Periodontol 2011;82:142-150.
29. Karched M, Furgang D, Sawalha N, Fine DH. Rapid identification of oral isolates of Aggregatibacter actinomycetemcomitans obtained from humans and primates by an ultrafast super convection based polymerase chain reaction. J Microbiol Methods 2012;89:71-75.
30. Naot D, Palmano K, Cornish J. Lactoferrin -A potential anabolic intervention in osteoporosis. In: Dionyssiotis Y, ed. Osteoporosis. New York: InTech; 2012:803-820, doi:10.5772/29652. Available at: http://www.intechopen. com/books/osteoporosis/lactoferrin-Apotential-Anabolic-intervention-in- osteoporosis. Accessed January 24, 2013.
31. Berlutti F, Pilloni A, Pietropaoli M, Polimeni A, Valenti P. Lactoferrin and oral diseases: Current status and perspective in periodontitis. Ann Stomatol (Roma) 2011;2:10-18.
32. Eberhard J, Drosos Z, Tiemann M, Jepsen S, Schroder JM. Immunolocalization of lactoferrin in healthy and inflamed gingival tissues. J Periodontol 2006;77:472-478.
33. Srivastava CH, Rado TA, Bauerle D, Broxmeyer HE. Regulation of human bone marrow lactoferrin and myeloperoxidase gene expression by tumor necrosis factor-Alpha. J Immunol 1991;146:1014-1019.
34. Groenink J, Walgreen-Weterings E, Nazmi K, et al. Salivary lactoferrin and low-Mr mucin MG2 in Actinobacillus actinomycetemcomitans-Associated periodontitis. J Clin Periodontol 1999;26:269-275.
35. Latorre D, Puddu P, Valenti P, Gessani S. Reciprocal interactions between lactoferrin and bacterial endotoxins and their role in the regulation of the immune response. Toxins (Basel) 2010;2:54-68.
36. Yamano E, Miyauchi M, Furusyo H, et al. Inhibitory effects of orally administrated liposomal bovine lactoferrin on the LPS-induced osteoclastogenesis. Lab Invest 2010;90:1236-1246.
37. Zimecki M, Artym J, Chodaczek G, Kocieba M, Kruzel ML. Protective effects of lactoferrin in Escherichia coli-induced bacteremia in mice: Relationship to reduced serum TNF alpha level and increased turnover of neutrophils. Inflamm Res 2004;53:292-296.
38. Graves D. Cytokines that promote periodontal tissue destruction. J Periodontol 2008; 79(Suppl. 8)1585-1591.
39. Silva TA, Garlet GP, Lara VS, Martins W JrJr., Silva JS, Cunha FQ. Differential expression of chemokines and chemokine receptors in inflammatory periapical diseases. Oral Microbiol Immunol 2005;20:310-316.
40. Annunziato F, Galli G, Cosmi L, et al. Molecules associated with human Th1 or Th2 cells. Eur Cytokine Netw 1998; 9(Suppl. 3)12-16.
41. Watford WT, Moriguchi M, Morinobu A, O'Shea JJ. The biology of IL-12: Coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 2003;14:361-368.
42. Spadaro M, Caorsi C, Ceruti P, et al. Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. FASEB J 2008;22:2747-2757.
43. Oba Y, Lee JW, Ehrlich LA, et al. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 2005;33:272-278.
44. Yu X, Huang Y, Collin-Osdoby P, Osdoby P. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res 2004;19:2065-2077.
45. Fine DH, Markowitz K, Furgang D, et al. Macrophage inflammatory protein-1alpha: A salivary biomarker of bone loss in a longitudinal cohort study of children at risk for aggressive periodontal disease? J Periodontol 2009;80:106-113.
46. Ferreira SB JrJr., Repeke CE, Raimundo FM, et al. CCR5 mediates pro-osteoclastic and osteoclastogenic leukocyte chemoattraction. J Dent Res 2011; 90:632-637.
47. Gonnelli S, Montagnani A, Caffarelli C, et al. Osteoprotegerin (OPG) and receptor activator of NFkB ligand (RANK-L) serum levels in patients on chronic hemodialysis. J Endocrinol Invest 2005; 28:534-539.
48. Cornish J. Lactoferrin promotes bone growth. Biometals 2004;17: 331-335.